Pioneer Announces Letter of Intent with NGMI Labs Inc.
Pioneer Media Holdings Inc. (“Pioneer” or the “Company”) is pleased to announce it has entered into a non-binding letter of intent ("LOI") with NGMI Labs Inc. (“NGMI”), a private British Columbia corporation, to acquire 100% of the issued and outstanding shares of NGMI (the “Acquisition”).
The proposed acquisition advances Pioneer’s investments in “web3” and businesses in the NFT, NFT gaming and tokenized community sectors.
Transaction Details
Under the Acquisition, Pioneer will acquire 100% of the outstanding shares of NGMI for a total consideration of 4,000,000 common shares of Pioneer, to be distributed on a pro rata basis to the NGMI shareholders. Pioneer, NGMI and the NGMI shareholders are at arm’s length.
Completion of the Acquisition is subject to standard conditions, including but not limited to the formalization of the Acquisition under a share purchase agreement, and the prior receipt of all requisite regulatory approvals, including the approval of the Canadian Securities Exchange (the “CSE”). Pioneer will have a 45-day exclusivity period to conduct due diligence on NGMI. Concurrent with, and as a condition to, the completion of the Acquisition, Matthew Shaw, founder of NGMI, will join the board of directors of Pioneer.
About NGMI:
Tokens and decentralized technology provide powerful new building blocks that empower communities to capitalize, govern and grow in ways that have never before been possible. DAO (Decentralized Autonomous Organization) tokens, and the emerging tools and platforms that support their operations, represent the most exciting sector of the web3 space, and NGMI has the access and talent to capitalize on the emerging trend.
“Our unique combination of hands-on operational experience (having launched and grown leading DAOs) and crypto capital markets experience, position us to bring broad mainstream support and capital to the emerging DAO ecosystem,” says Jess Sloss, co-founder of NGMI.
NGMI was founded by Jess Sloss, Gregg Peacock and Matthew Shaw. Each of these individuals will continue to provide their services and expertise to Pioneer and NGMI following completion of the Acquisition, and Mr. Shaw will be appointed to Pioneer’s board of directors.
Matt Shaw is active in the crypto and blockchain investment area having founded DeFi Yield Technologies (recently acquired by Dispersion Holdings), Protos Asset Management (a cryptocurrency asset management firm) and Blimp Technologies (dba Blimp Homes), a proptech company incorporating a crypto rewards ecosystem. Mr. Shaw is also a director of Argo Blockchain plc, listed on both the London Stock Exchange and NASDAQ.
Mr. Sloss has extensive experience in web 3 projects, both as an angel investor and as the host of the popular “Seed Club” podcast focusing on web3 and DAO ecosystems, as well as be a featured speaker on similar podcasts. Mr. Sloss is also the co-creator of Seed Club, an incubator for tokenized communities that has completed three cohorts.
Mr. Peacock co-founded SquiggleDAO in early 2021 with the vision of building a large, web3 community-owned collection of NFT art. Today, SquiggleDAO boasts 600 members collectively managing a $25M of tier 1 NFT art. He has also worked with technology start-ups since 2002 and blockchain since 2015 as an investor, trader and educator, and has extensive experience advising early-stage blockchain start-ups on product strategy and crypto economics.
Completion of the Acquisition is subject to numerous conditions as described above. There is no assurance or guarantee that the Acquisition will be completed as described or at all.
About Pioneer Media Holdings Inc.
Pioneer is an investment issuer that actively invests in and acquires a diversified portfolio of early-stage to mid-level companies in web3 including NFTs, NFT gaming and Tokenized Communities together with investments in Esports and mobile gaming. Pioneer’s management team leverages its global network to provide investors with access to investments not normally available to the average retail investor.
The current Pioneer portfolio includes investments such as: Leaf Mobile Inc. (TSX: LEAF), a leading free-to-play mobile games group; Guild eSports plc (LON: GILD), a global eSports business headquartered in London whose lead investor is David Beckham; Dynasty eSports Pte Ltd, creators of the world’s leading white-label Gaming Ecosystem Management solution, partnering exclusively on a B2B basis with Tier 1 telco's and large media organisations; and NFT Investments plc, a London based investment company focused on non-fungible tokens (“NFTs”).
Pioneer will continue its focus on web3 investments, including investments in businesses in the NFT, NFT gaming and tokenized community sectors.
Pioneer provides capital, experience, and support to these emerging market leaders while building shareholder value. Additional information about Pioneer is available at www.sedar.com.
Neither the Canadian Securities Exchange nor any Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Statements
Forward Looking Statements
This news release may contain “forward-looking” statements and information relating to the Company, the funds to be raised, and the use of any such funds that are raised, that are based on the beliefs of Company management, as well as assumptions made by and information currently available to Company management. There is no assurance the Company will be able to complete the placement on the terms as outlined above, or at all. The Company does not undertake to update forward‐looking statements or forward‐looking information, except as required by law.
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211125005961/en/
Contact information
ON BEHALF OF PIONEER MEDIA HOLDINGS INC.
Mike Edwards,CEO & Director, Via Tancredi
+44 203 434 2330
First Sentinel Corporate Finance Ltd (AQSE Corporate Adviser)
Brian Stockbridge / Gabrielle Cordeiro
+44 7876 888 011
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
